Danaher Corporation (DHR) Stock Price, Fundamentals & Analysis

What DHR does

Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments, covering areas such as cell culture media, chromatography resins, filtration technologies, aseptic fill finish, lab filtration, separation, purification, and healthcare filtration solutions. It is part of the S&P 500 and operates alongside peers such as Thermo Fisher Scientific (TMO), Labcorp (LH), and Quest Diagnostics (DGX).

Key numbers explained

• 221.56 USD is the current share price, the amount you pay for one share today.
• 39.4 is the trailing P/E ratio, which divides the current price by the last 12 months of earnings; it shows how much investors pay per dollar of recent earnings.
• 23.8 is the forward P/E ratio, based on expected future earnings, which can be more relevant for growth companies.
• 0.72% is the dividend yield, the annual dividend payment expressed as a percentage of the share price.
• 5.62 USD is the trailing 12-month earnings per share, the portion of net income allocated to each share.
• 0.81 is the beta, a measure of volatility relative to the market; below 1 means the stock has historically moved less than the market.
• 155.75B USD is the market capitalisation, the total value of all outstanding shares.
• 18.9% is the price change over the last 52 weeks, showing the total return from one year ago to today.

Recent news

• Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth
• MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
• Global Pharmaceutical Filtration Report highlights Danaher among companies reshaping the biologics manufacturing market.
• Bioreactors Market Outlook 2026-2035 features Danaher alongside Sartorius and Thermo Fisher Scientific.
• Danaher Schedules Third Quarter 2026 Earnings Conference Call.

What to watch

• Earnings growth and margins in the Biotechnology and Diagnostics segments, which drive revenue and profitability.
• The upcoming earnings call on 21 oct. 2026, where management will discuss results and outlook.
• The ex-dividend date of 30 sept. 2026, which determines eligibility for the next dividend payment.
• Competitive dynamics with peers such as Johnson & Johnson (JNJ), Medtronic (MDT), and Boston Scientific (BSX).
• Regulatory and policy developments in healthcare and diagnostics that can affect demand for laboratory and medical products.